COTXF (Coiled Therapeutics) Moat Score: 2/10 (As of Jun. 24, 2026)


COTXF Coiled Therapeutics PLC COTXF
21 GF Score
Price $0.15
! 4 Warning Signs
View Full Analysis

What is Coiled Therapeutics Moat Score?

Coiled Therapeutics COTXF 21 Moat Score is 2 as of Jun. 24, 2026. GuruFocus rates COTXF with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 1,405 Biotechnology companies, Coiled Therapeutics ranks better than 58.15% on this metric.

Coiled Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Coiled Therapeutics has No Moat: Coiled Therapeutics PLC lacks significant market leadership or proprietary technology. The company does not exhibit strong brand strength or customer loyalty, and there are no notable regulatory barriers or intellectual property that provide a competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Coiled Therapeutics might have No Moat - Very weak/transient advantages.

Coiled Therapeutics  (OTCPK:COTXF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Coiled Therapeutics Moat Score Related Terms

COTXF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Coiled Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coiled Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coiled Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Coiled Therapeutics's Moat Score falls into.


COTXF
21GF Score
Coiled Therapeutics PLC COTXF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Coiled Therapeutics (COTXF) has a Moat Score of 2 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Coiled Therapeutics ranks #588 out of 1405 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Coiled Therapeutics' Moat Score too high?
Coiled Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Coiled Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Coiled Therapeutics ranks #588 out of 1405 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Coiled Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Coiled Therapeutics' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Coiled Therapeutics ranks #588 out of 1405 companies for Moat Score. This puts Coiled Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Coiled Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coiled Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coiled Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coiled Therapeutics stock overvalued right now?
Coiled Therapeutics (COTXF) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Coiled Therapeutics' overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Coiled Therapeutics (COTXF), the current Moat Score is 2 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coiled Therapeutics Business Description

Other Exchanges COIL:UK0AG0:Germany
Address 85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Coiled Therapeutics PLC principal activity of the Company is to develop pre-clinical next generation medicines focused on hard-to-treat cancers. The Group operated in the single business segment of biotechnology.
21GF Score

Get the complete analysis for COTXF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price